» SIRT or sorafenib in patients with locally advanced HCC: SARAH and SIRveNIB trials

MEET THE EXPERTS ALL PROGRAMMES DEVELOPED COLLABORATIONS CONTACT

SIRT or sorafenib in patients with locally advanced HCC: SARAH and SIRveNIB trials

Dr. Mohamed Bouattour

Dr. Mohamed Bouattour from Hôpital Beaujon, APHP Clichy, France, discusses the SARAH and SIRveNIB trials in locally advanced HCC

Dr. Mohamed Bouattour

Hepatologist and Gastroenterologist

Beaujon University Hospital

France

Dr. Mohamed Bouattour

Hepatologist and Gastroenterologist

Beaujon University Hospital

France

Dr. Mohamed Bouattour is a physician in the Department of Digestive Oncology and Consultant in the Department of Hepatology at Beaujon University Hospital and has held this these positions since November 2007. He is board certified in Gastroenterology-Hepatology and Medical Oncology. He has expertise in the field of liver tumours, hepatocellular carcinoma, and pre-clinical and clinical research for liver disease. Dr. Bouattour works in close collaboration with a multidisciplinary team including, liver surgeons, radiologists, oncologists, hepatologists and pathologists, to improve the management of patients with liver cancers. Dr. Bouattour has been involved in presenting several collaborative works in national and international scientific meetings. He has authored and co-authored scientific papers in the field of liver and cancer diseases. He is investigator and sub investigator for several phase 1, 2 and 3 clinical trials. Dr. Bouattour is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology (ASCO). Relevant Publications Coriat R, Faivre SJ, Mir O, Dreyer C, Ropert S, Bouattour M, Desjardins R, Goldwasser F, Raymond E. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. Int J Nanomedicine 2016; 21; 11: 6207-6216. Bouattour M, Soubrane O, de Gramont A, Faivre S. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Trials 2016; 25; 17(1): 563. Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20):2245-63. Bouattour M, Rousseau B, Wassermann J, Payancé A, Huillard O. Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors? J Clin Oncol 2015; 33(22): 2484-5. Dreyer C, Sablin MP, Bouattour M, Neuzillet C, Ronot M, Dokmak S, Belghiti J, Guedj N, Paradis V, Raymond E, Faivre S. Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol 2015; 7(6): 910-5. Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, Boige V. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Invest New Drugs 2014; 32(5): 1028-35. Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist 2014; (4): 394-402. Ozenne V, Bouattour M, Goutté N, Vullierme MP, Ripault MP, Castelnau C, Valla DC, Degos F, Farges O. Prospective evaluation of the management of hepatocellular carcinoma in the elderly. Dig Liver Dis 2011; 43(12):1001-5.

Dr. Mohamed Bouattour has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

time | open 5 min | 2017

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

download resources

Download the slides

This programme was made for you: your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer and from Eisai Europe Limited.

Other programmes of interest

Prof Valentina Guarneri

Interactive patient case

28 min

(TEST) Oral SERDs: New Endocrine Therapy Options in ER+ Advanced ...

Sep 2023

Prof. Viktor Grünwald

Interactive patient case

11 min

Optimising treatment for advanced RCC

Jun 2023

Prof. David Hong

5 min

TRK fusion-positive cancer highlights from ASCO 2022

Jun 2022

Beth Wittmer

Prof. Hans Prenen

Podcast

20 min

Podcast: management of skin toxicity with multikinase inhibitors

Jun 2022

Prof. Chiara Cremolini

2 min

Update from ASCO 2022 - Rectal cancer & mCRC

Jun 2022

Prof. Sammy Saab

15 min

Response to immunotherapy in HCC: Real-world experience and treat...

Jun 2022

Prof. Jonathan Trent

2 min

Update from ASCO 2022 - Sarcoma

Jun 2022

Prof. Jonathan Trent

0 min

[DEMO] SARCOMA CONNECT update from ASCO 2022

May 2022

Screenshot of the video by Prof. Rebecca Dent

Dr. Rebecca Dent

Prof. Chiara Cremolini

Asst. Prof. Hans Lee

Prof. Jonathan Trent

0 min

Update From ASCO 2022 - Selected LBAs

May 2022

Brenda Martone

Assoc. Prof. Alicia Morgans

Podcast

30 min

Shared decision-making in nmCRPC: Treatment considerations to mai...

Jun 2022

Assoc. Prof. Tanya Dorff

Dr. Neal Shore

Podcast

30 min

Timing of ARSI and taxanes for mCRPC

Jun 2022

Assessing the management of hepatocellular cancer in Asia

Survey

2 min

Assessing the management of hepatocellular cancer in Asia

Jun 2022

Other programmes developed by Dr. Mohamed Bouattour

Dr. Mohamed Bouattour

Hepatologist and Gastroenterologist

Beaujon University Hospital

France

Prof Richard Finn

Dr. Mohamed Bouattour

Prof. James Harding

And others...

E-learning

83 min

Accreditation: EACCME

Appropriate selection of patients for 1st line monotherapy in adv...

Feb 2022

Dr. Mohamed Bouattour

0 min

The SARAH study in advanced HCC: implications for clinical practi...

2019

Dr. Mohamed Bouattour

5 min

HCC CONNECT update from AASLD 2016 #2

2016

Dr. Mohamed Bouattour

5 min

A CONNECT Update from ESMO 2017

2017

Dr. Mohamed Bouattour

5 min

Sequential sorafenib and regorafenib in patients with advanced HC...

2018

Dr. Mohamed Bouattour

5 min

HCC CONNECT Update from WCGIC 2020

Jul 2020

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.